VAXESS

December 11, 2020

Solving the challenges of infrastructure, logistics, and manufacturing for COVID-19 Vaccines

Vaxess

The Only Single-Dose, Shelf-Stable, Self-Applied SARS-CoV-2 Vaccine

Vaxess continues to advance its single-dose, shelf stable COVID vaccine with support from BARDA. In recent studies, Vaxess has shown that the MIMIX patch leads to a 50x enhancement in immune responses over a traditional IM injection, opening the door to single-dose protection. The MIMIX patch has also shown stability for weeks at room temperature, an important step to improving global vaccination rates. The data will be release in an upcoming publication.

[Read the full article here ]